These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 14902500)

  • 1. Insulin preparations with prolonged action.
    LENS J
    Acta Physiol Pharmacol Neerl; 1951; 2(2):302-4. PubMed ID: 14902500
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical investigations on new preparations of prolonged action insulin; zinc-insulin preparation for daily injection].
    JERSILD M; HALLAS-MOLLER K; PETERSEN K; SCHLICHTKRULL J
    Sem Med; 1954 Jul; 105(3):110-4. PubMed ID: 13195807
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible pegylation of insulin facilitates its prolonged action in vivo.
    Shechter Y; Mironchik M; Rubinraut S; Tsubery H; Sasson K; Marcus Y; Fridkin M
    Eur J Pharm Biopharm; 2008 Sep; 70(1):19-28. PubMed ID: 18495444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin's 85th anniversary--An enduring medical miracle.
    Heller S; Kozlovski P; Kurtzhals P
    Diabetes Res Clin Pract; 2007 Nov; 78(2):149-58. PubMed ID: 17482306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of the structure of insulin preparations for clinical practice].
    Svacina S
    Vnitr Lek; 2009 Apr; 55(4):409-11. PubMed ID: 19449759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged insulin treatment inhibits GH signaling via STAT3 and STAT1.
    Xu J; Ji S; Venable DY; Franklin JL; Messina JL
    J Endocrinol; 2005 Mar; 184(3):481-92. PubMed ID: 15749807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
    Higashi T; Hirayama F; Misumi S; Arima H; Uekama K
    Biomaterials; 2008 Oct; 29(28):3866-71. PubMed ID: 18620750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.
    Shechter Y; Mironchik M; Rubinraut S; Saul A; Tsubery H; Fridkin M
    Bioconjug Chem; 2005; 16(4):913-20. PubMed ID: 16029032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins.
    Whittingham JL; Jonassen I; Havelund S; Roberts SM; Dodson EJ; Verma CS; Wilkinson AJ; Dodson GG
    Biochemistry; 2004 May; 43(20):5987-95. PubMed ID: 15147182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery.
    Kwon JH; Lee BH; Lee JJ; Kim CW
    Eur J Pharm Sci; 2004 Jun; 22(2-3):107-16. PubMed ID: 15158896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin with prolonged action].
    Policlinico Prat; 1958 Mar; 65(9):345-6. PubMed ID: 13553833
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin.
    Panesar P
    Prof Nurse; 2004 Dec; 20(4):51-2. PubMed ID: 15624624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quest for physiologic insulin replacement.
    Owens DR
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):4-12. PubMed ID: 19667674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of absorption promoters on insulin absorption through colon-targeted delivery.
    Katsuma M; Watanabe S; Kawai H; Takemura S; Sako K
    Int J Pharm; 2006 Jan; 307(2):156-62. PubMed ID: 16289574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro release of insulin and biocompatibility of in situ forming gel systems.
    Kang F; Singh J
    Int J Pharm; 2005 Nov; 304(1-2):83-90. PubMed ID: 16181752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery.
    Xiong XY; Li YP; Li ZL; Zhou CL; Tam KC; Liu ZY; Xie GX
    J Control Release; 2007 Jul; 120(1-2):11-7. PubMed ID: 17509718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel iron-polysaccharide multilayered microcapsules for controlled insulin release.
    Zheng J; Yue X; Dai Z; Wang Y; Liu S; Yan X
    Acta Biomater; 2009 Jun; 5(5):1499-507. PubMed ID: 19231303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin detemir, does a new century bring a better basal insulin?
    Hordern SV; Russell-Jones DL
    Int J Clin Pract; 2005 Jun; 59(6):730-9. PubMed ID: 15924603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.